It has been established that patients with rheumatoid arthritis (RA) have decreased muscle and increased fat compared to those without RA.
Kidney involvement in systemic lupus erythematosus (SLE, lupus) is an important predictor of and contributor to morbidity and mortality from lupus. The approach to treatment for lupus nephritis is that of an induction phase of therapy (with cyclophosphamide vs mycophenolate mofetil) followed by long-term maintenance therapy. However, the optimal agent for chronic immunosuppression to prevent relapse or worsening of renal SLE is unknown.
The development of antidrug antibodies to biologic therapies, notably drugs that consist of monoclonal antibodies (such as adalimumab and infliximab) has been reported in patients with rheumatoid arthritis. However, the clinical significance of these antidrug antibodies in the long-term follow up of RA patients is unknown.